Pharmala Biotech Holdings Inc. (CSE:MDMA)
0.1550
+0.0150 (10.71%)
Aug 10, 2026, 3:47 PM EST
Pharmala Biotech Holdings Revenue
Pharmala Biotech Holdings had revenue of 513.23K CAD in the quarter ending May 31, 2026, with 279.70% growth. This brings the company's revenue in the last twelve months to 1.27M, up 201.24% year-over-year. In the fiscal year ending August 31, 2025, Pharmala Biotech Holdings had annual revenue of 605.50K, down -41.51%.
Revenue (ttm)
1.27M
Revenue Growth
+201.24%
P/S Ratio
12.06
Revenue / Employee
n/a
Employees
n/a
Market Cap
15.29M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Aug 31, 2025 | 605.50K | -429.80K | -41.51% |
| Aug 31, 2024 | 1.04M | 503.29K | 94.60% |
| Aug 31, 2023 | 532.00K | 453.93K | 581.44% |
| Aug 31, 2022 | 78.07K | - | - |
| Aug 31, 2021 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Pharmala Biotech Holdings News
- 11 days ago - PharmAla reports Q3 revenue C$513,000 vs. C$135,000 last year - TheFly
- 11 days ago - PharmAla Issues Q3 Financial Statements and AGM Update - GlobeNewsWire
- 12 days ago - Pharmala Biotech Holdings Registration statement: Q3 2026 - Filings
- 12 days ago - Pharmala Biotech Holdings Registration statement: Q3 2026 - Filings
- 12 days ago - Pharmala Biotech Holdings Earnings release: Q3 2026 - Filings
- 20 days ago - PharmAla enters up to $100M ALA-002 license pact with Jupiter Neurosciences - TheFly
- 20 days ago - PharmAla Biotech Executes Definitive License Agreement Granting Jupiter Neurosciences Exclusive U.S. Rights to ALA-002 - GlobeNewsWire
- 5 weeks ago - PharmAla Completes GMP Manufacturing of Drug Substance components for ALA-002 Provides Corporate Update Regarding ALA-002 Asset - GlobeNewsWire